Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Semaglutide and cardiovascular outcomes in obesity without diabetes

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF…. New England Journal of Medicine 2023

Document identifier
CEI-BR-067
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH
Title
Semaglutide and cardiovascular outcomes in obesity without diabetes
Source
New England Journal of Medicine
Year
2023
Volume, issue, pages
389(24):2221–2232
Digital object identifier
10.1056/NEJMoa2307563
PubMed identifier
37952131
Record type
Journal article
Institute identifier
CEI-BR-067

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Monograph: CagriSema (cagrilintide with semaglutide)Compound monograph
Trial abstract: SELECTTrial abstract
Synthesis: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonistsEvidence synthesis
Synthesis: Percentage weight change as a surrogate outcomeEvidence synthesis
Synthesis: Cardiovascular benefit in primary compared with secondary preventionEvidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
12 citing documents.

§1.3Subject tags

semaglutide cardiovascular SELECT

Compound Evidence Institute · CEI-BR-067 · https://compoundevidence.com/bibliography/lincoff2023/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.